PulseCath iVac Receives Positive Reimbursement Decision For Hospitals Across Germany

Arnhem, The Netherlands, January 30, 2015, the German Institute for the Hospital Remuneration System (InEK) today announced that the iVAC Intra-Aortic Catheter With Para-Corporal Pump for car­diac sup­port of the left ven­tri­cle has received German Neue Untersuchungs und Behandlungsmethoden (NUB) Status 4 approval across 14 lead­ing hos­pi­tals in Germany, a deci­sion from German reg­u­la­tors that may pos­i­tive­ly influ­ence reim­burse­ment from insur­ance com­pa­nies for the costs of iVAC pro­ce­dures .
“This pos­i­tive reim­burse­ment deci­sion sig­ni­fies an impor­tant step for­ward toward hav­ing iVAC Intra-Aortic Catheter with Para-Corporal Pump incor­po­rat­ed into the German DRG sys­tem,” stat­ed Torsten Heilmann, Chief Executive Officer, from the exclu­sive dis­trib­u­tor AVIDAL. “It is also emblem­at­ic of the strong clin­i­cian inter­est we are see­ing in Europe and will be the basis for the sig­nif­i­cant expan­sion of our com­mer­cial­iza­tion efforts. We look for­ward to increas­ing our col­lab­o­ra­tion with the German clin­i­cal com­mu­ni­ty and broad­en­ing the avail­abil­i­ty of our ther­a­py to addi­tion­al patients suf­fer­ing from Heart Failure.”
The approval was grant­ed under the German Institute for the Hospital Remuneration System (InEK) NUB pro­gram for facil­i­tat­ing the intro­duc­tion of inno­v­a­tive tech­nolo­gies that address under­served patient pop­u­la­tions. The NUB pro­gram pro­vides ther­a­pies with a stream­lined path to inclu­sion in the German DRG sys­tem. With a des­ig­na­tion of Status 4, the 14 approved hos­pi­tals may now request reim­burse­ment from their asso­ci­at­ed insur­ance com­pa­nies to cov­er the costs of iVAC pro­ce­dures.

Leave a Reply

Your email address will not be published. Required fields are marked *